Brokerages Set Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) PT at $15.00

Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) have received an average recommendation of “Moderate Buy” from the nine brokerages that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $18.3333.

EPRX has been the subject of several recent research reports. William Blair initiated coverage on Eupraxia Pharmaceuticals in a research note on Monday, March 23rd. They issued an “outperform” rating for the company. HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of Eupraxia Pharmaceuticals in a research note on Monday, May 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Tuesday, April 21st. Wall Street Zen cut Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Finally, Stifel Nicolaus initiated coverage on Eupraxia Pharmaceuticals in a research note on Thursday, May 21st. They issued a “buy” rating and a $25.00 price target for the company.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

Several institutional investors have recently made changes to their positions in EPRX. Integrated Wealth Concepts LLC bought a new stake in shares of Eupraxia Pharmaceuticals in the third quarter valued at approximately $71,000. Bank of America Corp DE boosted its stake in shares of Eupraxia Pharmaceuticals by 402.4% in the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after buying an additional 10,059 shares during the period. Aptus Capital Advisors LLC bought a new stake in shares of Eupraxia Pharmaceuticals in the fourth quarter valued at approximately $76,000. Guardian Wealth Advisors LLC NC bought a new stake in Eupraxia Pharmaceuticals during the fourth quarter worth $76,000. Finally, Geode Capital Management LLC bought a new stake in Eupraxia Pharmaceuticals during the fourth quarter worth $105,000.

Eupraxia Pharmaceuticals Price Performance

Eupraxia Pharmaceuticals stock opened at $7.53 on Wednesday. Eupraxia Pharmaceuticals has a 12 month low of $3.82 and a 12 month high of $9.32. The stock’s 50 day moving average is $7.16 and its 200-day moving average is $7.36. The company has a current ratio of 19.31, a quick ratio of 19.31 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $455.07 million, a price-to-earnings ratio of -7.17 and a beta of 1.19.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its earnings results on Tuesday, May 12th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.01). Equities research analysts expect that Eupraxia Pharmaceuticals will post -0.86 EPS for the current year.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.